Clinical Trial Detail

NCT ID NCT03302234
Title Study of Pembrolizumab Given With Ipilimumab or Placebo in Participants With Untreated Metastatic Non-small Cell Lung Cancer (MK-3475-598/KEYNOTE-598)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements yes
Sponsors Merck Sharp & Dohme Corp.
Indications

non-small cell lung carcinoma

Therapies

Pembrolizumab

Ipilimumab + Pembrolizumab

Age Groups: adult senior

Additional content available in CKB BOOST